An open label study evaluating the antiviral activity and safety of Fuzeon [enfuvirtide] in triple-class experienced HIV-1 infected patients changing their therapy to a standard of care regimen which includes initiating an integrase inhibitor in an expanded access program plus optimized background.

Trial Profile

An open label study evaluating the antiviral activity and safety of Fuzeon [enfuvirtide] in triple-class experienced HIV-1 infected patients changing their therapy to a standard of care regimen which includes initiating an integrase inhibitor in an expanded access program plus optimized background.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Enfuvirtide (Primary) ; Antiretrovirals; Raltegravir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms AMICI
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 17 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top